News

The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.

The data, from the phase 3 COMET trial, will be the basis for global regulatory submissions in the second half of 2020, according to manufacturer Sanofi.

The Women's Alzheimer's Prevention Center becomes the first medical clinic in the US to offer a women-specific center for Alzheimer disease prevention, research, and caregiving support.

In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.

Neurology News Network for the week ending June 20, 2020.

The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the anticipated impact of the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.

Treatment needs of those with high frequency episodic migraine may be similar to those with low frequency chronic migraine.

The neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis and co-principal investigator of the CAVS-MS study discusses the reasons for the high rates of misdiagnosed MS.

The online conference theme for this year is "Coming of Age with Multiple Sclerosis," and will feature the top neurologists and specialists within the multiple sclerosis community.

The director of the Neurology Residency Program at Weill Cornell Medicine details his first-hand experience working in the epicenter of the COVID-19 pandemic and how his department adapted.

In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.

Patients with pre-concussion migraines that occurred at a rate of >1 per month had a greater number of concussion symptoms and burden over 12 weeks.

Data presented at AHS 2020 suggest that 170-mg oral atogepant (Allergan) was both safe and well-tolerated, setting the stage the continued development in migraine prevention.

The drug, previously approved for Parkinson disease psychosis, received breakthrough therapy designation for this new indication.

Data from a pair of phase 3 studies suggest that the recently approved celecoxib oral solution (Elyxyb; Dr. Reddy’s Laboratories) offers safe and effective acute treatment of episodic migraine.

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed how this year has proved that telemedicine is likely here to stay.

Infants born to pregnant women with chronic migraine who received treatment with onabotulinumtoxinA did not show any physical, intellectual, or social disabilities.

The newly developed MRI techniques aimed at treating those with Parkinson disease could lead to better outcomes and fewer side effects.

The results help to better understand the unique risk profiles of people with different subtypes of migraine.

The clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research at Cleveland Clinic details the interventions for men with MS and how the study can change the discussion on masculinity norms.

Results from the CHAMP trial of adolescents and children with migraine add to the already active and ongoing discussion surrounding the use of preventives in this population.

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.

Further studies are needed to confirm the additional reductions in monthly headache days observed in patients with migraine who were treated with onabotulinumtoxinA and an add-on CGRP agent.

The $7.2 million grant will evaluate central vein sign as a biomarker for multiple sclerosis diagnosis.

Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.

Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.